Monday, November 25, 2024

AAO Urges UnitedHealthcare to Add Ophthalmology to 'Gold Card' Program

Ophthalmic procedures should be added to program that eases prior-authorization burden on physicians and practices, says the Academy.

Friday, November 22, 2024

Does Blood Pressure Variability Affect Visual Field Loss in Glaucoma?

Higher mean BP and higher BP variability were associated with faster VF deterioration.

By Sarah Fackler

Thursday, November 21, 2024

Positive Phase 4 Results for Cequa for Dry Eye Disease

Sun Pharmaceuticals presented the data on patients switched to Cequa at the 2024 ESCRS meeting in Barcelona

Thursday, November 21, 2024

SpyGlass Completes Tigris Trial Enrollment for Treatment of Glaucoma, Ocular Hypertension

The Phase 1/2 trial will compare the IOP-reducing effect of SpyGlass Pharma's bimatoprost-eluting IOL to treatment with timolol ophthalmic solution in glaucoma patients undergoing cataract surgery.

Thursday, November 21, 2024

Cencora Acquiring Retina Consultants of America

The $4.6 billion deal expands the drug wholesaler’s presence in specialty health care and retinal care. 

Wednesday, November 20, 2024

Positive Phase 3 Topline Efficacy Results for Melt Pharmaceuticals' Sublingual Sedative

Opioid-free Melt-300 showed itself to be safe and effective for patients undergoing cataract surgery.

Tuesday, November 19, 2024

Ocugen Reports Preliminary Data from Gene Therapy Trial to Treat GA

Six-month results from the ArMaDa trial for OCU410, a 1-time therapy delivered via subretinal injection, demonstrated safety and functional vision benefits for GA patients.

Tuesday, November 19, 2024

FDA Grants Rare Pediatric Disease, Fast Track Designations for Stargardt Treatment

In both TEASE-1 and TEASE-3, gildeuretinol demonstrated a favorable safety and tolerability profile with no adverse events related to hyper- or hypo-vitaminosis A such as xerophthalmia, chromatopsia, dark adaptation delays or night blindness.

Tuesday, November 19, 2024

Adverum’s Ixo-vec Shows Positive Results in nAMD Trials

Data from the LUNA trial, as well as the OPTIC extension study, show a reduction in anti-VEGF injections along with a favorable safety profile. The company is planning a Phase 3 trial for 2025.

Monday, November 18, 2024

FDA Accepts Resubmitted NDA for DED Treatment, Expands AbbVie Option Agreement

The FDA accepted for review the resubmitted NDA for Aldeyra Therapeutics' topical ocular reproxalap for the treatment of dry eye disease, assigning a Prescription Drug User Fee Act date of April 2, 2025. Aldeyra also announced the expansion of its exclusive option agreement with AbbVie Inc.

Monday, November 18, 2024

Phase 3 Study for Pediatric Progressive Myopia Fails to Meet Primary Endpoint

Eyenovia’s Phase 3 study evaluating its proprietary drug-device combination of low-dose atropine in the company’s Optejet dispensing platform as a potential treatment for pediatric progressive myopia did not meet its primary endpoint. 

Friday, November 15, 2024

Trial Shows Lenses Could be a Safe, Effective Alternative to Daily Glaucoma Drops

The study demonstrated that LL-BMT1, in a 32-µg dose, achieved equivalent IOP reduction to bimatoprost 0.01% drops.

Wednesday, November 13, 2024

Harrow Launches Access and Affordability Program, Partners with GoodRx

The company's initiative includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx to provide patients with discounts on select Harrow products.

Wednesday, November 13, 2024

FDA Extends Review Period for Neurotech's MacTel Therapy

The PDUFA date for Neurotech Pharmaceuticals's NT-501 has been pushed to March 2025.

Wednesday, November 13, 2024

Phase 3 Trial Initiated for EyePoint's Duravyu

The primary endpoint will be changes in BCVA at weeks 52 and 56, with secondary measures including safety and the need for supplemental injections. 

Tuesday, November 12, 2024

Harrow's Vevye Wins a Place in Key Formularies

Millions more patients will have access to the dry eye treatment in 2025.

Tuesday, November 12, 2024

AlloVir, Kalaris Announce Merger to Create Company Focused on Retina Diseases

The combined company will focus on the development of TH103, a novel therapy for patients with neovascular and exudative retinal diseases. 

Tuesday, November 12, 2024

LifeLink Tissue Bank, BioTissue Join Forces

LifeLink Tissue Bank announced a strategic relationship with BioTissue to enhance the use of placental tissue recovered following healthy deliveries, which BioTissue will transform into therapies for patients in need.

Tuesday, November 12, 2024

What Does AMD Cost Patients and Caregivers?

Researchers found not only substantial direct and indirect medical costs, but also significant effects on well-being and productivity.

By Sarah Fackler

Tuesday, November 12, 2024

Konan Medical USA Launches objectiveFIELD Perimeter

The objectiveFIELD bilateral visual field analyzer measures pupillary responses to spatially resolved stimuli, captured by video cameras under infrared conditions.

Thursday, November 7, 2024

PulseSight Therapeutics Presents New Data on Geographic Atrophy Therapy

Findings from a retrospective study on PST-611, the company's transferrin vectorized treatment, were presented at EVER Congress 2024. 

Tuesday, November 5, 2024

FDA Fast Track Designation Granted for Treatment to Prevent Retinopathy of Prematurity

FELIQS plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the United States and Japan in 1Q2025

Tuesday, November 5, 2024

Prevent Blindness Provides Free Resources for Diabetes-related Eye Disease Awareness Month

Prevent Blindness provides the public and professionals with free web pages, fact sheets, educational videos, toolkits, and social media graphics, to help prevent vision loss and blindness from diabetes.

Tuesday, November 5, 2024

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD

Valeda provides an improvement in BCVA over 24 months of >5 letters or equivalent to a line on the eye chart.

Monday, November 4, 2024

CMS Issues Final CY 2025 Payment Rate Regulation for HOPDs, ASCs

Under the final rule, ASC payment rates will be updated by 2.9% in 2025, representing an average across all ASC procedures.

Friday, November 1, 2024

EyePoint Reports Positive Interim Data for DME Therapy

EyePoint Pharmaceuticals' DURAVYU 2.7 mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline.

Monday, October 28, 2024

SpyGlass Pharma Releases Positive Data on Drug-eluting IOL

Patients with glaucoma or ocular hypertension implanted with SpyGlass Pharma’s Drug Delivery Platform showed a mean 43.7% reduction in IOP at 18 months, compared to baseline. 

Monday, October 28, 2024

FDA Taps Dr. Michelle Tarver as Permanent CDRH Director

The CDRH is responsible for overseeing the safety, effectiveness, and quality of medical devices and radiation-emitting products in the United States.

Monday, October 28, 2024

Survey Shows Significant Gap in Caregivers’ Understanding of Retinal Conditions

Survey findings show fewer than 30% of caregivers of persons at risk for retinal diseases have heard about some of the most common types of diseases that affect older adults.

Thursday, October 24, 2024

First Patient Dosed in First Clinical Trial to Treat Neuropathic Corneal Pain

OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial, the company said.

Thursday, October 24, 2024

Trial Shows Positive Results for Retinal Implant

Patients with late stage dry AMD regained the ability to read and recognize faces after receiving the PRIMA retinal implant.

Wednesday, October 23, 2024

Study: Ophthalmic Spray Microdosing May Help Minimize Harmful Effects of BAK

A recently published study found that microdose spray with Eyenovia’s Optojet reduces the harmful effect of preservatives in eyedrops.

Wednesday, October 23, 2024

Ocuphire Pharma Announces Acquisition of Opus Genetics

The acquisition creates a clinical-stage company with a strong focus on gene therapies for rare inherited retinal diseases.

Monday, October 21, 2024

Glaukos Announces Positive Phase 3 Results for Keratoconus Treatment

Phase 3 confirmatory trial met pre-specified primary efficacy endpoint and demonstrated excellent tolerability and a favorable safety profile through 12 months

Monday, October 21, 2024

LENZ's Presbopia Drug Granted New Drug Application

LNZ 100 is the first and only aceclidine-based eyedrop to improve near vision in people with presbyopia, the company says.

Monday, October 21, 2024

Eye Health America, Verséa Ophthalmics Enter Preferred Partnership

The agreement supports the management of ocular surface disease and ocular surgery.

Friday, October 18, 2024

AAO Partners with FundamentalVR to Launch Virtual Reality Education Program

AAO hopes the VR Education program will help ophthalmologists expand their skills in diagnosing and treating eye diseases.

Tuesday, October 15, 2024

Alcon Brings its Latest to AAO 2024

The company's meeting offerings include making its new Voyager Direct Selective Laser Trabeculoplasty for glaucoma therapy available for demonstration, debuting gas delivery systems, and presentation of data for pivotal drug and surgical products. 

Tuesday, October 15, 2024

Centricity Vision to Introduce New Enhancements for ZEPT0Link at AAO

Adjustable suction time parameters will increase OR efficiency, the company says.

Tuesday, October 15, 2024

Beyeonics to Launch Beyeonics One with Invisible Light Technology at AAO 2024

The infrared technology penetrates dense cataracts, hemorrhages and cloudy corneas, offering a clear visual pathway.

Tuesday, October 15, 2024

FDA Grants Clearance for Heidelberg’s SPECTRALIS Flex Module

The multimodal, diagnostic imaging-only platform is designed for imaging the posterior segment of pediatric and adult patients in a supine position.

Tuesday, October 15, 2024

Bausch + Lomb’s enVista Envy Full Range of Vision IOL Approved by FDA

enVista Envy IOLs will be commercially available in the United States on a limited basis in the coming weeks and more broadly in 2025.

Friday, October 11, 2024

iCare Introduces a New Slit Lamp Tonometer

The iCare ST500 offers a combination of iCare rebound technology and slit lamp-based tonometry

Thursday, October 10, 2024

Phase 3 Trial for MELT-300, a Needle- and Opioid-free Sedative for Patients Undergoing Cataract Surgery, Doses Last Patient

The clinical trial reaches another milestone, with topline results expected by year's end. And the FDA agrees to a Special Protocol Assessment.

Thursday, October 10, 2024

ZEISS Expands Ophthalmic Offerings With New Digital AI Tools, Surgical Solutions

At the AAO annual meeting, ZEISS will showcase digital enhancements and surgical solutions across cataract, corneal refractive, retina and glaucoma workflows.

Wednesday, October 9, 2024

Partnership Formed to Launch AI-Powered SMO to Bring Trials to OBS Centers

The collaboration between CASExGLOBAL, Clinical AI and iOR Partners introduces AI-powered Site Management Organization bringing decentralized clinical trials to ophthalmic office-based surgery centers.

Wednesday, October 9, 2024

Clearside Reports Positive Phase 2b Data in Wet AMD Trial

ODYSSEY Phase 2b trial of suprachoroidal CLS-AX in wet AMD achieved all primary and secondary outcomes.

Monday, October 7, 2024

Aldeyra Therapeutics Resubmits Reproxalap NDA for the Treatment of DED

Topical ocular reproxalap is an investigational new drug candidate for the treatment of signs and symptoms of dry eye disease.

Monday, October 7, 2024

Ocuphire Publishes Phase 3 Results of Ryzumvi for Pharmacologically Induced Mydriasis Reversal

Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically induced mydriasis with favorable safety profile

Thursday, October 3, 2024

Harrow Announces Relaunch of Triesence

After 2 years unavailable in the United States, the corticosteroid is once again on the market.

Thursday, October 3, 2024

Priovant Therapeutics' Phase 3 Brepocitinib Trial Begins for Uveitis

FDA grants fast track designation for nonanterior noninfectious uveitis treatment.

Wednesday, October 2, 2024

Johnson & Johnson Rolls Out TECNIS Odyssey Next-Generation IOL

New presbyopia-correcting IOL offers cataract patients precise vision at every distance in any lighting.

Tuesday, October 1, 2024

NextGen Introduces AI-Driven Ambient Listening Solution

This latest release is tailored to support the workflows of ophthalmology and optometry, and to address the specific challenges and limitations of using ambient listening to document eye exams.

Monday, September 30, 2024

STAAR Surgical's Center Helps Surgeons Address Growing Rates of Myopia in the US

The company offers expanded training on Implantable Collamer Lenses for surgeons and their staffs.

Friday, September 27, 2024

Zeiss Introduces Ultrasound-free Lens Extraction Device

The company says the Micor 700’s non-ultrasound approach minimizes thermal stress and tissue damage during cataract surgery.

Friday, September 27, 2024

Regener-Eyes Unveils New Preservative-Free Multi-Dose Bottle

The bottle enhances the effectiveness of the preservative-free solution, ensuring safe eyedrop administration for daily and long-term use

Friday, September 27, 2024

Eyenovia Launches Clobetasol for Inflammation, Pain Following Ocular Surgery

Clobetasol propionate ophthalmic suspension 0.05% provides a twice-a-day dosing regimen for ocular surgery patients. 

Wednesday, September 25, 2024

Lumibird Launches AI-Assisted Imaging for OSD

The device integrates multiple exams such as transillumination meibography and an autofocus HD camera for sharp image quality and automatic, accurate and reproducible results.

Tuesday, September 24, 2024

Phase 2b SIGLEC Trial Enrollment Complete

The trial will compare intravitreal injection of AVD-104 to avacincaptad pegol for treatment of geographic atrophy secondary to AMD.

Tuesday, September 24, 2024

Chronic Stress Linked to Glaucoma Risk, NIH Study Finds

Research also highlights a potential link between allostatic load, which is a stress measurement, and racial disparities in glaucoma prevalence.

Tuesday, September 24, 2024

Visionix USA Debuts Solix OCT/OCT-A with New Topography Module

A new topography module has been added to Visionix USA's next-generation Optovue Solix FullRange and Solix Essential OCT and OCT angiographer systems. 

Tuesday, September 24, 2024

MST to Distribute Vista Products Globally

Collaboration introduces Vista 1-Step and Vista IS products, which are intended to enhance vitrectomy procedures.

Tuesday, September 24, 2024

Nicox Announces Glaukos Option Agreement

The agreement aims to explore the therapeutic potential of Nicox’s nitric oxide-donating PDE5 inhibitor, NCX 1728, in glaucoma treatment.

Tuesday, September 24, 2024

Ripple, AbbVie to Partner on Glaucoma Treatment

The collaboration focuses on developing RTC-620, a biodegradable implant that is designed to reduce IOL.

Tuesday, September 24, 2024

Bel-sar Shows Encouraging Results in Trial

In early-stage choroidal melanoma patients, suprachoroidal injection of bel-sar shows 80% tumor control and 90% vision preservation.

Tuesday, September 24, 2024

Gildeuretinol Acetate Reduces GA Lesion Growth

Data from the SAGA study showed patients with geographic atrophy showed improved visual acuity after 2 years on the oral therapy.

Friday, September 20, 2024

Aflibercept Biosimilar Shows Equivalent Efficacy in DME Trial

MYL-1701P proves comparable to reference aflibercept at 52 weeks, according to data from the INSIGHT clinical trial.

Friday, September 20, 2024

Dr. Andrea Govetto Receives First Ramin Tadayoni Award

The award, recognizing his innovative research in macular edema, was presented at the EURETINA meeting.

Thursday, September 19, 2024

Atsena’s ATSN-201 Secures Orphan Drug Status

The FDA designation advances a potential gene therapy treatment for X-linked retinoschisis. 

Thursday, September 19, 2024

Opthea Validates Sozinibercept Manufacturing Process

Completion of PPQ campaign for novel wet AMD treatment strengthens path to regulatory approval

Thursday, September 19, 2024

New Mapping Tool Provides Data for Children’s Vision, Eye Health

The Prevent Blindness Children’s Vision Health Map and corresponding report provides the public, professionals and policy makers with county and state-level data on children’s vision issues.

Wednesday, September 18, 2024

Study: First Whole-Eye, Partial-Face Transplant Recipient Achieves Viable Eye One Year After Surgery

In a surgical first, retinal cells showed light responsiveness up to 9.0 μv at 220 days after whole eye transplant, nearing the low end of normal (10-50 μv).

Monday, September 16, 2024

Compulink, Quantum AI Health Partner to Launch AI-Powered Ambient Medical Scribe

The technology leverages advanced generative artificial intelligence and machine learning to automatically listen to the physician and patient during consultations.

Saturday, September 14, 2024

FDA Approves OCTA Capability on Robotic Camera

Topcon’s Maestro2 becomes the first robotic device available in the United States to offer OCT angiography.

Saturday, September 14, 2024

Uveoscleral Glaucoma Treatment Shows Promising Results

Study demonstrates the effectiveness of Iantrek’s biointerventional technology in treating open-angle glaucoma.

Wednesday, September 11, 2024

OcuDyne’s OPTiC System Trial Shows Positive Results for GA

Study demonstrated a positive safety profile and met secondary and exploratory endpoints associated with subjective and objective evidence of visual function preservation at 6 months.

Wednesday, September 11, 2024

Viridian’s Phase 3 THRIVE Trial Shows Promising Results for TED

Veligrotug (VRDN-001) achieved all primary and secondary endpoints 

Monday, September 9, 2024

CMS Seeks Feedback on Medicare Contractor Consolidation

Agency considers merging jurisdictions and extending contracts to improve efficiency.

Monday, September 9, 2024

CMS Reports Potential Data Breach

Medicare beneficiaries may be affected by vulnerability in third-party software.

Monday, September 9, 2024

Phase 2b/3 Trial Launched for DME Treatment

Restoret, a potential first-in-class therapy, to be tested for diabetic macular edema.

Monday, September 9, 2024

New ScribeRyte AI Technology to Automate Clinical Notetaking

ScribeRyte AI health-care documentation solutions automates charting on a customizable platform for medical networks and hospitals. 

Monday, September 9, 2024

Ocuphire Initiates VEGA-3 and LYNX-2 Phase 3 Trials

The VEGA-3 Phase 3 clinical trial is evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia; and the LYNX-2 Phase 3 trial is evaluating Phentolamine Ophthalmic Solution 0.75% in patients with decreased visual acuity under low light conditions following keratorefractive surgery. 

Wednesday, September 4, 2024

Study Shows CureSight’s Superiority Over Patching

Patients using the CureSight digital eye-tracking device for amblyopia treatment achieved greater visual acuity gains in per-protocol analysis.

Wednesday, September 4, 2024

Rayner to Launch Spiral IOL Designed with AI

A proprietary AI engine trained on patient outcomes helped create RayOne Galaxy’s spiral, which delivers a continuous full range of vision with minimized dysphotopsia,

Tuesday, September 3, 2024

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Trials for DED

The FDA has accepted protocols and endpoints for signs and symptoms of PL9643 Phase 3 pivotal clinical trials for dry eye disease

Tuesday, September 3, 2024

Haag-Streit Launches METIS Ophthalmic Microscope System

The system is intended for procedures like capsulorhexis and capsular polishing. 

Tuesday, September 3, 2024

AAO Sounds Alarm on OTC Eye Color-Changing Drops

The AAO warns these products have not been tested for safety or efficacy and could potentially damage the eyes.

Tuesday, August 27, 2024

Bruder Introduces Eyeleve MGD Eyedrop Formula Under New Brand

Formerly Retaine MGD, the preservative-free ophthalmic emulsion for moderate to severe evaporative dry eye will launch in early 2025. 

Tuesday, August 27, 2024

Prevent Blindness Declares September Sports Eye Safety Month

Data shows more than 32,600 sports eye injuries were treated in 2023, with pool and water sports as the type of sport with the most eye injuries.

Monday, August 26, 2024

FTC Supports Proposed FDA Guidance on Interchangeable Biosimilar Drugs

Guidance would support biologic drug competition, increase patient access to biosimilars and lower health-care costs for patients, the FTC comment says.

Monday, August 26, 2024

Opus Genetics Wins Rare Pediatric Disease Designation from FDA

The company's ocular gene therapy is intended for patients with an inherited early onset retinal degeneration.

Thursday, August 22, 2024

Visionix Unveils the VX 610 Automated Fundus Camera

The new device features auto alignment, auto focus and auto capture functions.

Wednesday, August 21, 2024

Visiox Pharmaceuticals, Ocuvex Therapeutics to Merge

With the merger, the company will operate under the Ocuvex name.

Tuesday, August 20, 2024

FDA Grants Incentive to XLRS Gene Therapy

ATSN-201 aims to provide new hope for patients with X-linked retinoschisis.

Monday, August 19, 2024

Glenmark Launches OTC Solution for Eye Allergy Relief

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is an alternative to the active ingredient in Pataday Twice Daily Relief.

Monday, August 19, 2024

Lupin's Brimonidine Tartrate 0.025% Receives Tentative Nod from FDA

The drug is a generic equivalent to Bausch + Lomb's Lumify.

Monday, August 19, 2024

ASRS Campaign Shines Spotlight on Expert Retina Specialist Care

TV and radio spots highlight the importance of seeing a retina specialist to prevent blindness

Wednesday, August 14, 2024

Sandoz's Enzeevu Wins FDA Approval

The drug is indicated for treatment of neovascular AMD, also known as wet AMD.

Tuesday, August 13, 2024

ADA, Genentech to Bring Eye Health Equity Program to the DC Region

Program will focus on identifying and removing barriers to care facing Black and Hispanic/Latino communities in the Washington, DC region.   

Tuesday, August 13, 2024

Lupin Reports Successful Phase 3 Trials for Biosimilar for Wet AMD

Study achieved its primary endpoint of therapeutic equivalence in visual acuity improvement for wet AMD patients, showcasing comparable safety and immunogenicity between LUBT010 and Lucentis.

Tuesday, August 13, 2024

FDA Deems Ocular Therapeutix’ Trial Appropriate as a Registrational Study in Wet AMD

Phase 3 SOL-R clinical trial is acceptable for use as the company’s second adequate and well-controlled study of AXPAXLI for the treatment of wet AMD.

Tuesday, August 13, 2024

New CPT Code to Report PBM Therapy in Retinal Disease

Establishing a CPT code for photobiomodulation use in retina marks a positive step toward reimbursement.

Tuesday, August 13, 2024

Aldeyra’s Phase 3 Study Shows Promising Results for DED

Data revealed reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort. 

Monday, August 12, 2024

LENZ Therapeutics Submits NDA for Presbyopia Treatment

LNZ100 is an aceclidine-based ophthalmic solution intended to treat presbyopia.

Monday, August 5, 2024

Eyedaptic Unveils AI-Powered Visual Assistant for AMD, Other Retinal Disorders

The EYE6 with Ivy leverages advanced multimodal generative AI and large language models to help users improve their daily living experiences and independence.

Monday, August 5, 2024

Prevent Blindness Declares August Children’s Eye Health and Safety Month

Along with educational resources, the organization is drawing attention to legislation to fund children’s vision programs.

Monday, August 5, 2024

Topcon Incorporates Advanced Digital Technology Into New IS-6500 Ophthalmic Instrument Stand

The stand's features can be customized to allow the operator to program well cups and control room lights, reading lamp brightness and BIO brightness directly from the built-in touchscreen panel.

Monday, August 5, 2024

ASCRS Launches Summit to Enhance Refractive Cataract Surgery Practices

In-person summit will feature 18+ course hours and an extensive resource library to support practice adoption of advanced-technology IOLs

Monday, July 29, 2024

Eyenovia, Senju Sign Collaboration Agreement for New Chronic DED Treatment

Partnership to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet dispensing technology

Friday, July 26, 2024

Spryte Receives Breakthrough Device Designation from FDA for neuro OCT Technology

This designation expedites the technology’s development and review process and supports reimbursement and timely access for patients and health-care providers.

Thursday, July 25, 2024

Exosome Treatment Shows Promise for Optic Nerve Recovery

Preliminary results in a nonhuman trial indicate a potential pathway for recovery of optic nerve function in glaucoma patients.

Thursday, July 25, 2024

Ellipsoid Zone Integrity at Baseline Predicts Geographic Atrophy Progression Rate

Analysis of data from the GATHER trials found eyes with greater ellipsoid zone attenuation and larger EZ-GA gap showed faster GA growth over 12 months.

Thursday, July 25, 2024

Phase 2 LUNA Trial Data Presented at ASRS

A single injection of the gene therapy Ixo-vec reduced anti-VEGF injection burden by 90% to 95% in wet AMD patients.

Wednesday, July 24, 2024

Oertli's Faros Anterior Cataract Surgery System Receives FDA 510(k) Clearance

Faros is optimized for fast setup, with a readiness time of under one minute, making it ideal for integrating into office-based surgery.

Wednesday, July 24, 2024

Supplements Slow Geographic Atrophy Progression

New analysis shows benefit to taking AREDS2 formula vitamins during the late stage of dry age-related macular degeneration. 

Tuesday, July 23, 2024

Bausch + Lomb Acquires Diagnostic Company Trukera Medical

The acquisition will help expand Bausch + Lomb’s surgical presence in the United States.

Tuesday, July 23, 2024

Study: New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in DME, DR

Two-year Phase 3 data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat DME and DR

Thursday, July 18, 2024

EssilorLuxottica Signs Agreement to Acquire Majority Stake in Heidelberg Engineering

Heidelberg Engineering will continue to serve the market under its established brand

Tuesday, July 16, 2024

FDA Clears Heidelberg’s SPECTRALIS OCTA Module with SHIFT Technology

This next generation of OCT angiography reduces acquisition time by 50%.

Tuesday, July 16, 2024

Cornea Research Pioneer and Visionary Claes H. Dohlman, MD, PhD, Passes Away at 101

Dr. Dohlman is considered by many to be the father of modern corneal science, whose transformative work modernized the field and continues to be widely utilized today.

Monday, July 15, 2024

AAO, NANOS Issue Advice on Weight Loss Drug and Eye Health

A postmarketing surveillance study could be helpful in determining if there is a connection between semaglutide and NAION.

Monday, July 15, 2024

Promising Progress for Preservative-Free in Glaucoma

Preservative Freedom Coalition says having strong guidelines that support the use of preservative-free options will help build an environment that improves education on preservatives and will help break down barriers to access.

Friday, July 12, 2024

Merck Acquires EyeBio

The deal, valued at up to $3 billion, expands Merck’s ophthalmology pipeline.

Friday, July 12, 2024

Sickle Cell Drug Shows Promise in Stabilizing Vision in Rare Genetic Disease

Crizanlizumab shows promise in stabilizing vision and potentially modifying disease progression in patients with the rare genetic disorder RVCL-S.

Thursday, July 11, 2024

Cardiovascular Health Linked to Lower Retinopathy Risk in US Adults

Analysis of national data shows moderate to high cardiovascular health scores are associated with reduced odds of diabetic or hypertensive retinopathy.

Thursday, July 11, 2024

27-gauge Vitrectomy Shows Comparable Outcomes to 25-gauge in Trial

The vitrectomy systems had similar surgical times and complication rates, with 27-gauge allowing more sutureless surgeries.

Thursday, July 11, 2024

Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study

Phase 3 trials demonstrate faricimab’s potential to extend treatment intervals up to 16 weeks while maintaining visual gains in patients with diabetic macular edema.

Thursday, July 11, 2024

APX3330 Shows Promise in Slowing DR Progression

A Phase 2 trial of the drug demonstrates potential to delay or prevent progression of diabetic retinopathy.

Thursday, July 11, 2024

Optogenetic Therapy Shows Promise for Retinitis Pigmentosa

Results of the RESTORE trial indicate that MCO-010 optogenetic therapy significantly improves visual acuity in patients with retinitis pigmentosa.

Tuesday, July 9, 2024

CDRH Announces Expansion of TAP Program to Include Ophthalmic Devices

This includes devices reviewed in the Division of Ophthalmic Devices in fall 2024

Tuesday, July 9, 2024

Genentech to Reintroduce Susvimo for Patients with Wet AMD

The FDA approved updates to Susvimo, which will be available to US retina specialists and patients with wet AMD in the coming weeks

Tuesday, July 9, 2024

Alcon Completes Acquisition of BELKIN Vision

Purchase includes direct selective laser trabeculoplasty technology set to become available in late 2024.

Tuesday, July 9, 2024

Formycon Receives FDA Approval for FYB203/Ahzantive (aflibercept-mrbb) Biosimilar

The biosimilar was approved to treat patients with wet AMD and other retinal diseases 

Tuesday, July 9, 2024

FDA Approves Genentech’s Vabysmo Prefilled Syringe for Wet AMD, DME, RVO

The Vabysmo PFS will become available to US retina specialists and their patients in the coming months.

Tuesday, July 9, 2024

Bausch + Lomb Survey: Dry Eye Sufferers Struggle to Find Relief

New online resource, KnowYourDryEye.com, aims to increase awareness and education

Tuesday, July 2, 2024

Prevent Blindness Declares Fireworks Safety Awareness Week

Prevent Blindness urges the public to celebrate independence day safely by avoiding fireworks, attending authorized displays by professionals

Tuesday, July 2, 2024

Permanent J-code Now Effective for Glaukos iDose TR

Company says the new J-code simplifies and ensures consistent coverage

Tuesday, July 2, 2024

FDA Grants DeNovo Classification for Treatment to Lower IOP

Balance Ophthalmics’ non-pharmacological, non-surgical device intended to help manage IOP in normal tension and open-angle glaucoma patients.

Tuesday, July 2, 2024

Study: Home-based OCT Reduces Office Visits, Treatment Burden

Prospective trial shows impact of Home OCT guided wet AMD patient management 

Wednesday, June 26, 2024

FDA to Review License Application for NT-501

The ocular implant from Neurotech Pharmaceuticals is an investigational treatment for MacTel.

Wednesday, June 26, 2024

ANI Pharmaceuticals to Acquire Alimera Sciences

The $381 million deal expands ANI’s presence in ophthalmology.

Monday, June 24, 2024

Alcon’s Unity VCS and CS Receive FDA 510(k) Clearance

Vitreoretinal Cataract System and Cataract System are the first solutions to be introduced from Alcon’s Unity portfolio of surgical equipment

Friday, June 21, 2024

FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder

Approval was based on positive results from the CHAMPION-NMOSD Phase 3 trial.

Thursday, June 20, 2024

Harrow Provides Triesence Relaunch Update

Full production of Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL may be restarting later this year after 5 years on the FDA Drug Shortage list. 

Wednesday, June 19, 2024

FDA Grants Aurion Biotech BTD and RMAT Designations for AURN001

AURN001 is the first allogeneic cell therapy to receive both FDA designations for the treatment of corneal edema secondary to corneal endothelial disease.

Wednesday, June 19, 2024

Phase 2 Study Shows Promising Results for Sjögren’s disease

Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70% relative average improvement on the primary endpoint compared to patients who received placebo. 

Tuesday, June 18, 2024

Lifestyle Habits Tied to Myopia Development

Learn about effective prevention and treatment options for myopia, including lifestyle changes and advanced management strategies.

Tuesday, June 18, 2024

Portable Device Cleared for DR Screening and Diagnosis

AEYE Health recently announced FDA clearance for the AEYE Aurora, a handheld device from Optomed that can diagnose referable diabetic retinopathy from retinal images.

Tuesday, June 11, 2024

Oculis’ Phase 2 Study Shows Positive Results for DED

Improvements across multiple signs of efficacy endpoints were observed in the full population, and with a predictive and more pronounced effects in the TNFR1 genetic biomarker population

Tuesday, June 11, 2024

AMA Adopts New Policies for Prior Authorizations

House of Delegates approves reforms to deliver greater transparency and accountability on the part of insurers.

Monday, June 10, 2024

FDA Warns of Potential Safety Risks with Sulfite-containing Compounded Drugs

Among the complaints reported were conjunctivitis, itchy eyes, swollen eyelids and respiratory failure    

Monday, June 10, 2024

Harrow’s Phase 3 Study Shows Promising Results for DED

Water-free cyclosporine 0.1% ophthalmic solution shown to be safe and well tolerated during long-term use

Friday, June 7, 2024

Will Daily Low-Dose Aspirin Help Prevent Macular Degeneration?

A study found that low-dose daily aspirin does not prevent the development or progression of AMD in older adults.

Friday, June 7, 2024

Eversight, LighTopTech Partner to Advance Ophthalmic Imaging

Collaboration aims to improve imaging modalities for eye tissues in both clinical and research settings

Wednesday, June 5, 2024

Bausch + Lomb Launches Nutritional Supplement for Dry Eyes

Blink NutriTears targets key root causes of dry eyes and promotes healthy tear production

Wednesday, June 5, 2024

Nidek Presents a New OCT Tailored for Glaucoma and Retinal Practices

The RS-1 Glauvas delivers greater efficiency, patient comfort and accruate, early imaging.

By Rene Luthe

Wednesday, June 5, 2024

Lumibird Medical Launches Handheld Pachymeter

POCKET III features a measurement range from 150 μm to 1200 μm.

Tuesday, June 4, 2024

Nordic Pharma Introduces LACRIFILL Canalicular Gel

Dry eye therapy temporarily blocks tear drainage by the occlusion of the canalicular system

Tuesday, June 4, 2024

BioTissue Introduces CAM360 AmnioGraft

Therapy treats patients with mild to moderate DED and other ocular surface conditions

Thursday, May 30, 2024

ZEISS Adds OCT Enhancements to CIRRUS 6000

The device is now supported with an OCT reference database and advanced cybersecurity features. 

Wednesday, May 29, 2024

FDA Approves AAO Assessment Tool for Premium IOLs

Premium IOL researchers can use the tool to evaluate patient-reported symptoms.

By Rene Luthe

Wednesday, May 29, 2024

Merck to Acquire EyeBio

Acquisition expands Merck’s presence in ophthalmology

Wednesday, May 29, 2024

Retinal Disease Research Grants Awarded

Inaugural grants aim to help advance research into retinal diseases caused by mutations in the PRPH2 gene.

Tuesday, May 28, 2024

Enrollment Completed in Phase 3 Program for Wet AMD

Opthea Limited program will assess safety and superior efficacy of sozinibercept for the treatment of patients with wet AMD. 

Thursday, May 23, 2024

GONIOTOMY DEVICE WINS FDA'S 510K CLEARANCE

Adult glaucoma patients get a new option as New World Medical's KDB Glide receives indication expansion.

By Rene Luthe

Tuesday, May 21, 2024

PREVENT BLINDNESS OFFERS NEW STARGARDT DISEASE EDUCATIONAL RESOURCES

Free resources include webpage, fact sheets, expert interview video and social media graphics.

Tuesday, May 21, 2024

FDA APPROVES INTERCHANGEABLE BIOSIMILAR AFLIBERCEPT

Yesafili is a VEGF inhibitor that targets several ophthalmology conditions

Friday, May 17, 2024

HAAG-STREIT LAUNCHES 3D OPTION FOR IMAGING MODULE 910

Imaging module features a second 4K camera aimed at increasing detail

Thursday, May 16, 2024

NOTAL VISION'S HOME OCT RECEIVES DE NOVO AUTHORIZATION

The FDA gives AI-powered home retinal imaging service its marketing authorization for novel medical devices.

By Rene Luthe

Thursday, May 16, 2024

FDA CLEARS REICHERT TONO-VERA TONOMETER

Handheld tonometer provides IOP measurements and eliminates the need for topical anesthetic.

Tuesday, May 14, 2024

PHASE 2 STUDY SHOWS PROMISING RESULTS FOR GEOGRAPHIC ATROPHY

Annexon's ANX007 provided broad-based protection against vision loss and protected key retinal structures.

Tuesday, May 14, 2024

LEGISLATION INTRODUCED TO ADDRESS CHILDREN'S VISION AND EYE HEALTH

'Early Detection of Vision Impairments for Children Act' is a bipartisan proposal.

Tuesday, May 14, 2024

EYECRO REPORTS POSITIVE DATA FOR DRY EYE TREATMENT

MiDROPS shown safe and effective for moderate to severe DED in Phase 2 trial.

Friday, May 10, 2024

EYE2GENE, HEIDELBERG ANNOUNCE COLLABORATIVE PARTNERSHIP

Alliance aims to advance ophthalmic diagnostics and personalized treatment approaches

Thursday, May 9, 2024

TOPCON, MICROSOFT PARTNER TO DELIVER AI-POWERED SOLUTIONS

‘Healthcare from the Eye’ aims to improve health care access, cost and quality

Wednesday, May 8, 2024

Quick Notes: May 8, 2024

Johnson & Johnson debuts EYE-RD Global Registry; RetiSpec, Topcon to develop AI diagnostic tool; and more. 

Wednesday, May 1, 2024

Quick Notes: May 1, 2024

FDA approves LUMIFY preservative-free eyedrops; FDA clears fully autonomous AI for portable DR screening; and more.

Wednesday, April 24, 2024

Quick Notes: April 24, 2024

Positive data for MGD treatment; new research could unlock immunotherapy for rare eye cancer; and more.

Wednesday, April 17, 2024

Quick Notes: April 17, 2024

Regeneron issues response to DOJ filing related to Eylea; iHealthScreen awarded patent on AI glaucoma detection model; and more.

Wednesday, April 10, 2024

Quick Notes: April 10, 2024

Positive Phase 3 data for presbyopia treatment; RxSight launches its newest Light Adjustable Lens, the LAL+; and more.

Monday, April 8, 2024

READING THE SIGNS OF GLAUCOMA

Experts discuss recent advances in glaucoma diagnostics.

By Jim Gallagher, senior managing editor

Monday, April 8, 2024

NEED FOR SPEED

The VisuMax 800 femtosecond laser, recently approved by the FDA, demonstrates power and efficiency.

By Jim Gallagher, senior managing editor

Monday, April 8, 2024

SURGERY CENTERS ON THE UPSWING

OOSS celebrates a year of successes, welcomes new board leadership at Perspective 2024 luncheon.

By Jim Gallagher, senior managing editor

Monday, April 8, 2024

WHEN THINGS GO WRONG

Anterior segment surgeons provide pearls for crisis management.

By Jim Gallagher, senior managing editor

Monday, April 8, 2024

GOING GREEN IS A HEALTHY CHOICE

ASCRS and ASOA leaders encourage clinics and surgery centers to reduce waste and embrace sustainable practices.

By Jim Gallagher, senior managing editor

Sunday, April 7, 2024

PRESBYOPIA TREATMENT ROUNDUP

Experts discussed the various options to treat aging eyes.

By Jim Gallagher, senior managing editor

Sunday, April 7, 2024

OFFICE-BASED SURGERY

Proponents of ophthalmic office-based surgery believe that it provides an ideal way to address the growing need for cataract surgery.

Sunday, April 7, 2024

A PLETHORA OF PEARLS

Useful tips and techniques for anterior segment surgeons was the focus of ASCRS lecture.

By Jim Gallagher, senior managing editor

Sunday, April 7, 2024

GROW YOUR PRACTICE REVENUE

Experts provide tips and strategies to help ophthalmic practices thrive despite declining reimbursement.

By Jim Gallagher, senior managing editor

Sunday, April 7, 2024

AN UPDATE ON PRESBYOPIA DROPS

Although the initial response has been tepid, presbyopia-correcting drops can still be an excellent choice for certain patients.

By Jim Gallagher, senior managing editor

Saturday, April 6, 2024

ASCRS SUBSPECIALTY DAY: FOCUS ON CORNEA

Sessions focused on the latest innovations and techniques in corneal care, as experts presented case studies and surgical videos.

By Jim Gallagher, senior managing editor

Saturday, April 6, 2024

SPEAKING OUT FOR FAIR PAY

Experts discuss what's in store for physician reimbursement in 2024 at ASOA session.

By Jim Gallagher, senior managing editor

Saturday, April 6, 2024

CHANGES, HONORS AT ASCRS MEETING

New ASCRS president takes office, and deserving surgeons are honored for their accomplishments 

By Jim Gallagher, senior managing editor

Saturday, April 6, 2024

WHAT WOULD ROGER DO?

Surgeons discuss the benefits of refractive lens exchange in Steinert Lecture 

By Jim Gallagher, senior managing editor

Saturday, April 6, 2024

FOCUS ON GLAUCOMA

Experts use real-world case studies to discuss surgical techniques and clnical advances in glaucoma treatment. 

By Jim Gallagher, senior managing editor

Wednesday, April 3, 2024

Quick Notes: April 3, 2024

J&J debuts Tecnis Odyssey IOL; Viatris launches RYZUMVl for mydriasis; and more.

Wednesday, March 27, 2024

Quick Notes: March 27, 2024

CMS assigns J-code for GA treatment; glaucoma Mont Blanc Phase 3 trial results; and more. 

Wednesday, March 20, 2024

Quick Notes: March 20, 2024

Congress passes partial fix to Medicare physician payment; NovaBay, Eyenovia to co-promote prescription ophthalmic products; and more.

Wednesday, March 13, 2024

Quick Notes: March 13, 2024

Regeneron reports positive data for treatment of wet AMD, DME; drug-eluting contact lens study shows sustained IOP reduction; and more.

Wednesday, March 6, 2024

Quick Notes: March 6, 2024

Glaukos’ iDose TR commercially available in the US; CorNeat EverPatch synthetic tissue launched in US; and more.

Wednesday, February 28, 2024

Quick Notes: February 28, 2024

Four eye ointments voluntarily recalled; CoFi announces market-wide availability of financing solution with CareCredit; and more.

Wednesday, February 21, 2024

Quick Notes: February 21, 2024

New AI products designed to improve efficiency; FDA grants Breakthrough Device Designation for spectacle lenses; and more. 

Wednesday, February 14, 2024

Quick Notes: February 14, 2024

Meridian receives FDA approval for the MR Q family of lasers; Study shows Vyzulta’s safety, effectiveness at reducing IOP; and more.

Wednesday, February 7, 2024

Quick Notes: February 7, 2024

FDA warns of contaminated copycat eyedrops; Genentech reports positive long-term data for Vabysmo; and more. 

Wednesday, January 31, 2024

Quick Notes: January 31, 2024

AAO warns against eye color-changing surgeries; new company Eyconis formed to develop Ascendis Pharma ophthalmology assets; and more.

Wednesday, January 24, 2024

Quick Notes: January 24, 2024

MIGS device market growth rate of more than 5% expected; Outlook receives FDA agreement for trial; and more.

Wednesday, January 17, 2024

Quick Notes: January 17, 2024

FDA clears Zeiss femtosecond laser for nearsightedness; NIDEK introduces scanning laser ophthalmoscope; and more.

Wednesday, January 10, 2024

Quick Notes: January 10, 2024

FDA approves Bausch + Lomb’s TENEO LASIK platform for myopia and myopic astigmatism; Alcon reports positive data for DED treatment; and more.

Wednesday, January 3, 2024

Quick Notes: January 3, 2024

Five Medicare Administrative Contractors retired their local coverage determinations for MIGS that were scheduled to take effect on Jan. 29, 2024; Harrow partners with three health-care technology platforms to expand US availability of VEVYE; and more.